MedTrace Logo

RISS Block for Enhanced Recovery After Video-Assisted Thoracoscopic Surgery

NCT07462273 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-03-10

No results posted yet for this study

Summary

This prospective randomized controlled trial evaluates the efficacy and safety of ultrasound-guided rhomboid intercostal and subserratus plane (RISS) block for postoperative analgesia in patients undergoing video-assisted thoracoscopic surgery (VATS).

Postoperative pain after VATS can impair respiratory function, delay mobilization, and increase opioid consumption. Although several regional anesthesia techniques are available, the optimal analgesic strategy remains under investigation. The RISS block is a novel fascial plane block that may provide effective thoracic analgesia while minimizing opioid-related adverse effects.

A total of 90 adult patients scheduled for elective VATS will be randomly assigned to receive either ultrasound-guided RISS block combined with general anesthesia or general anesthesia alone. The primary outcomes include postoperative 24-hour benefit of analgesia score (BCS) and patient-controlled intravenous analgesia (PCIA) pressing frequency. Secondary outcomes include postoperative pain scores, opioid consumption, and adverse events.

This study aims to determine whether RISS block improves postoperative recovery and reduces opioid requirements after VATS.

Conditions

  • Postoperative Pain
  • Thoracic Surgery
  • Video-Assisted Thoracic Surgery

Interventions

PROCEDURE

Intercostal nerve block

Ultrasound-guided intercostal nerve block performed at surgical port levels (T4-T7) using 0.375% ropivacaine with total dose ≤75 mg.

PROCEDURE

Rhomboid Intercostal and Subserratus Plane Block with local anesthetic

Ultrasound-guided dual-plane RISS block performed after induction of general anesthesia. A total of 40 mL of 0.375% ropivacaine (150 mg) was administered across the rhomboid-intercostal plane and low subserratus plane.

Sponsors & Collaborators

  • Ningbo University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2025-09-01
Completion
2025-10-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07462273 on ClinicalTrials.gov